Study of 23ME-01473 in Patients With Advanced Solid Malignancies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06290388 |
Recruitment Status :
Recruiting
First Posted : March 4, 2024
Last Update Posted : March 22, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Solid Tumor | Drug: 23ME-01473 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 82 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2a, Multicenter, Open-label, Dose Escalation and Expansion Study of Intravenously Administered 23ME-01473 in Participants With Advanced Solid Malignancies |
Actual Study Start Date : | March 7, 2024 |
Estimated Primary Completion Date : | June 30, 2026 |
Estimated Study Completion Date : | June 30, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Phase 1
Participants will receive escalating doses of 23ME-01473
|
Drug: 23ME-01473
23Me-01473 given by intravenous infusion |
- Phase 1:Incidence and severity of dose-limiting toxicities (DLTs) [ Time Frame: First dose through 21 days post dose ]
- Phase 1: Incidence and severity of adverse events (AEs) [ Time Frame: From Screening through 90 days post treatment ]
- Phase 1 Incidence and severity of serious adverse events (SAEs) [ Time Frame: From Screening through 90 days post treatment ]
- ORR based on investigator assessment against RECIST 1.1 criteria [ Time Frame: From baseline until disease progression (up to 5 years) ]
- Phase 1: Prevalence and incidence of antidrug antibodies (ADA) to 23ME-01473 [ Time Frame: From first dose up to 5 days post treatment discontinuation ]
- Phase 1: Objective response rate (ORR) [ Time Frame: From baseline until disease progression (up to 5 years) ]ORR based on investigator assessment against RECIST 1.1 criteria
- Duration of response (DoR) [ Time Frame: From baseline until disease progression (up to 5 years) ]Duration of response based on investigator assessment against RECIST 1.1 criteria
- Disease Control Rate (DCR) [ Time Frame: From baseline until disease progression (up to 5 years) ]Disease control rate based on investigator assessment against RECIST 1.1 criteria
- Progression free survival (PFS) [ Time Frame: From baseline until disease progression (up to 5 years) ]Progression free survival based on investigator assessment against RECIST 1.1 criteria
- Time of maximum serum concentration (Tmax) following a single dose of 23ME-01473 [ Time Frame: [Time Frame: Cycle 1 (21 days, from Cycle 1 Day 1 predose to Cycle 2 Day 1 predose)] ]
- Area under the concentration-time curve from zero to the last measurable concentration (AUClast) following a single dose of 23ME-01473 [ Time Frame: [Time Frame: Cycle 1 (21 days, from Cycle 1 Day 1 predose to Cycle 2 Day 1 predose)] ]
- Last measurable serum concentration (Clast) following a single dose of 23ME-01473 [ Time Frame: [Time Frame: Cycle 1 (21 days, from Cycle 1 Day 1 predose to Cycle 2 Day 1 predose)] ]
- Area under the concentration-time curve from zero extrapolated to infinity (AUCinf) following a single dose of 23ME-01473 [ Time Frame: [Time Frame: Cycle 1 (21 days, from Cycle 1 Day 1 predose to Cycle 2 Day 1 predose)] ]
- Terminal half-life (T1/2) following a single dose of 23ME-01473 [ Time Frame: [Time Frame: Cycle 1 (21 days, from Cycle 1 Day 1 predose to Cycle 2 Day 1 predose] ]
- Maximum serum concentration (Cmax) following multiple doses of 23ME-01473 [ Time Frame: [Time Frame: Cycle 4 (21 days, from Cycle 4 Day 1 predose to Cycle 5 Day 1 predose)] ]
- Time of maximum serum concentration (Tmax) following multiple doses of 23ME-01473 [ Time Frame: [Time Frame: Cycle 4 (21 days, from Cycle 4 Day 1 predose to Cycle 5 Day 1 predose)] ]
- Area under the concentration-time curve from time zero to the end of the dosing interval (AUCtau) following multiple doses of 23ME-01473 [ Time Frame: [Time Frame: Cycle 4 (21 days, from Cycle 4 Day 1 predose to Cycle 5 Day 1 predose)] ]
- Serum concentration at the end of the dosing interval (Ctau) following multiple doses of 23ME-01473 [ Time Frame: [Time Frame: Cycle 4 (21 days, from Cycle 4 Day 1 predose to Cycle 5 Day 1 predose)] ]
- Terminal half-life (T1/2) following multiple doses of 23ME-01473 [ Time Frame: [Time Frame: Cycle 4 (21 days, from Cycle 4 Day 1 predose to Cycle 5 Day 1 predose)] ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 110 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Phase 1: Adults ≥ 18 years of age
- Phase 1: Histologically-diagnosed locally advanced (unresectable), or metastatic carcinoma or sarcoma that has progressed after standard therapy for the specific tumor type.
- Adults 18+: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy ≥ 12 weeks
- Phase 1: Participants with evaluable disease are eligible regardless of tumor type, RECIST 1.1 can be used to assess disease progression.
Exclusion Criteria:
- Females who are pregnant (positive serum pregnancy test within 7 days prior to study drug administration) or breastfeeding.
-
Immune-Related Medical History
- Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years
- Receipt of systemic immunosuppressive therapy (e.g. steroids) within 4 weeks prior to the start of study drug administration
- History of idiopathic pulmonary fibrosis, interstitial lung disease, organizing pneumonia, non-infectious pneumonia that required steroids, or evidence of active, non-infectious pneumonitis
- History of Grade ≥ 3 immune-mediated toxicity
- Prior allogeneic or autologous bone marrow transplant, or other solid organ transplant
-
History of a positive test for:
- Hepatitis C virus (HCV) infection, except for those who have completed curative therapy for HCV and have undetectable HCV RNA
- Hepatitis B virus (HBV) infection, except for those who are receiving treatment with HBV-active nucleos(t)ide antiviral therapy at the time of study entry and have undetectable HBV DNA
- Human Immunodeficiency Virus (HIV) infection, except those who meet the following criteria: CD4+ T cells ≥ 350 cells/μL, no history of Acquired Immunodeficiency Syndrome (AIDS)-defining opportunistic infections, HIV RNA < 50 copies/mL, and on a stable antiretroviral regimen for at least 3 months
- Prior anticancer therapy, including chemotherapy, targeted therapy, biological therapy or immune-checkpoint inhibitors within 4 weeks or 5 drug half-lives (whichever is shorter)
- History of another malignancy in the previous 2 years, unless cured by surgery alone and continuously disease free.
- Uncontrolled or symptomatic CNS (central nervous system) metastases and/or carcinomatous meningitis
- Recent history (within 6 months) of serious cardiovascular disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06290388
Contact: Study Inquiry | 650-963-8997 | studyinquiry@23andme.com |
United States, Texas | |
START Center for Cancer Care | Recruiting |
San Antonio, Texas, United States, 78229 |
Study Director: | Jennifer Low, M.D,Ph.D | 23andMe, Inc. |
Responsible Party: | 23andMe, Inc. |
ClinicalTrials.gov Identifier: | NCT06290388 |
Other Study ID Numbers: |
23ME-01473-CLIN-001 |
First Posted: | March 4, 2024 Key Record Dates |
Last Update Posted: | March 22, 2024 |
Last Verified: | March 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Cancer Phase 1 Solid Tumor Oncology |
NK ULBP6 Immunotherapy |
Neoplasms |